Outsourcing-Pharma.com presents its latest round up of career moves in the pharmaceutical industry, including news from Theorem, FMC Technologies and EMD Serono.
Theorem Clinical Research has drafted in Shannon Gordon as VP of global project management.
She joins the firm from PRA International, where she was senior director of project delivery.
In her new role, Gordon takes charge of the oversight of project management activities including quality deliverables, staff, project status and budget oversight.
Tech solutions provider FMC Technologies has named Robert Potter its new president.
He takes the reins from John Gremp, who stepped down to focus on his role as chairman and CEO of the firm.
Potter was previously executive VP of energy systems for the firm.
"Bob is an experienced and well-respected leader with a deep understanding of our markets and technologies," said Gremp.
Merck KGaA’s life sciences division EMD Millipore has named John Kamerud the new principle scientific director for discovery and development solutions in the bioscience business unit.
The former Covance associate director will now work on compliance and regulatory efficiency for development, validation, and application of assays.
Jim Hulse, managing scientific director of discovery and development solutions for North America said: "His extensive biopharmaceutical and service industry experience will be critical as we continue to expand our large molecule bioanalytical services to meet our client’s drug development requirements"
Meanwhile, Merck KGaA’s biopharma branch EMD Serono has hired Thorsten Eickenhorst as US chief medical officer and head of US development.
Eickenhorst will work with the regulatory, medical and development teams to boost the firm’s clinical activities in the US.
He joins the company from Biogen Idec where he was VP of clinical development and medical research.
Annalisa Jenkins, executive VP and head of global drug development and medical for Merck Serono, said: “He will play a key role on our US and global management teams as we continue to strengthen our regulatory, medical and development footprint in the biopharmaceutical market.”
ShangPharma Corporation has appointed Yuk Lam Lo has been appointed as chairman of the board’s independent committee.
The committee was created earlier this month to evaluate CEO Michael Xin Hui’s proposal to take the company private.
In a statement the firm said further appointments will follow. The statement added that no definitive timetable for action has yet been set.
Jill Schwieters will join the Advisory Board of the Women Business Leaders of the US Health Care Industry Foundation (WBL).
Currently president of recruitment solutions provider Pinstripe Healthcare, Schwieters said of her new role: “The WBL is a wonderful organisation that has a very important impact on the industry we serve.
“Pinstripe Healthcare has always played an active role in the foundation and I am honoured to take a seat on their board among so many well respected healthcare thought leaders.”
Healthcare ad agency AbelsonTaylor has named Bill Hyland, Tonya Waypa and Rachael Arons Gelman as senior copywriters.
Hyland will work on products in the cardiovascular arena, Waypawill be focus on biologics and oncology, and Gelmanwill work with a product for the treatment of GERD (gastroesophageal reflux disease).